Similarly, inhibition of CaMKII, which is known to be responsible for ICaL and ryanodine receptor phosphorylation as well as INaL regulation, appears to be an important therapeutic target for suppressing arrhythmias in HF [13], [17], [63]. Here, CAMK2G is linked to cardiac arrhythmia.